Please Note: This trial is no longer enrolling new participants
A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of Intermediate Fit Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance.
| Protocol No. | CTO-S2209 | Scope | National |
|---|---|---|---|
| Principal Investigator | Attaya Suvannasankha | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
